金迪克(688670) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 decreased by 103.09% year-on-year, amounting to -6,299,040.71 RMB, and the year-to-date revenue decreased by 45.16% to 120,843,721.03 RMB[5] - The net profit attributable to shareholders for Q3 2023 was -46,158,115.69 RMB, a decline of 163.34% compared to the same period last year, while the year-to-date net profit decreased by 119.92% to -11,077,111.92 RMB[5] - The basic and diluted earnings per share for Q3 2023 were both -0.37 RMB, reflecting a decrease of 162.71% year-on-year[6] - Total revenue for Q3 2023 was CNY 120,843,721.03, a decrease of 45.2% compared to CNY 220,360,267.77 in Q3 2022[22] - Operating profit for Q3 2023 was CNY -16,709,645.06, compared to CNY 62,361,247.47 in Q3 2022, indicating a significant decline[22] - Net profit for Q3 2023 was CNY -11,077,111.92, down from CNY 55,615,583.65 in Q3 2022, reflecting a negative shift in profitability[22] Research and Development - The total R&D investment for Q3 2023 was 9,647,068.95 RMB, a decrease of 14.37% year-on-year, while the year-to-date R&D investment decreased by 30.30% to 25,037,301.36 RMB[6] - Research and development expenses for Q3 2023 were CNY 12,049,272.55, a decrease of 51.5% from CNY 24,861,620.02 in Q3 2022[22] - The company has not disclosed any new product launches or technological advancements during this reporting period[14] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was 61,761,430.14 RMB, an increase of 152.56% year-on-year[6] - As of September 30, 2023, the company's cash and cash equivalents amounted to ¥430,569,549.73, a significant increase from ¥174,728,926.82 at the end of 2022, representing a growth of approximately 146.9%[17] - The company's accounts receivable decreased to ¥121,762,747.28 from ¥341,111,680.20, indicating a reduction of about 64.3%[17] - The total current assets decreased to ¥820,509,618.89 from ¥951,015,539.38, a decline of about 13.8%[17] - The ending cash and cash equivalents balance for Q3 2023 was approximately $430.57 million, significantly higher than $123.41 million at the end of Q3 2022, marking an increase of 248.5%[27] - The total cash inflow from operating activities in Q3 2023 was approximately $329.42 million, while total cash outflow was about $267.66 million, resulting in a net cash inflow of approximately $61.76 million[26] Production and Operational Issues - The company experienced a temporary production halt leading to no sales in Q3, and there were returns of 47,500 units sold in the first half of the year, impacting revenue[10] - The company experienced a temporary shutdown of its influenza vaccine production line due to environmental issues, leading to the scrapping of all products produced during the affected period from July 7 to July 14, 2023[15] - The company plans to resume production of the quadrivalent influenza vaccine following successful environmental recovery and testing, aiming for a swift return to normal operations[16] - The company reported an increase in inventory, which may impact future cash flow and operational efficiency[15] - The company has implemented strict quality control measures in response to the environmental issues, ensuring product safety and compliance[15] - The management is focused on risk assessment and quality assurance to mitigate the impact of the temporary production halt on overall performance[15] Assets and Liabilities - The total assets at the end of the reporting period were 1,719,214,714.58 RMB, a decrease of 5.89% from the end of the previous year[6] - The equity attributable to shareholders at the end of the reporting period was 1,430,994,786.30 RMB, a decrease of 1.96% from the end of the previous year[6] - Total liabilities for Q3 2023 were CNY 288,219,928.28, a decrease from CNY 367,105,051.87 in Q3 2022[19] - The total non-current assets as of Q3 2023 were CNY 898,705,095.69, an increase from CNY 875,761,410.71 in the previous period[19] Financing Activities - The company raised $66 million in borrowings during Q3 2023, compared to $47 million in Q3 2022, reflecting a 40.4% increase in financing activities[27] - The net cash flow from financing activities for Q3 2023 was approximately $10.02 million, a substantial increase from $2.21 million in Q3 2022[27] - The company's cash flow from financing activities included dividend payments of approximately $18.98 million in Q3 2023, compared to $44.79 million in Q3 2022, showing a decrease of 57.6%[27]